Endothelial and platelet function alterations in HIV-infected patients

Area of Science:

• Cardiology
• Infectious Diseases
• Immunology

Background:

• The global human immunodeficiency virus (HIV) epidemic affects millions, with significant impact on children.
• Highly Active Antiretroviral Therapy (HAART) has improved patient survival and quality of life.
• HAART introduction has led to previously unrecognized complications, notably ischemic cardiovascular events.

Purpose of the Study:

• To review evidence linking chronic HIV infection and HAART to endothelial dysfunction and platelet alterations.
• To explore the role of different HAART regimens in cardiovascular complications.
• To discuss potential pathophysiologic mechanisms and therapeutic implications.

Main Methods:

• Literature review of studies on HIV, HAART, atherosclerosis, endothelial dysfunction, and platelet activation.
• Analysis of evidence associating cardiovascular events with HIV infection versus HAART.
• Examination of proposed pathophysiologic pathways.

Main Results:

• Chronic HIV infection is associated with premature atherosclerosis, including coronary, cerebrovascular, and peripheral arterial disease.
• Endothelial dysfunction and platelet activation are identified as markers of atherosclerosis and increased cardiovascular risk in HIV patients.
• Specific HAART drugs, such as abacavir, have been implicated in myocardial infarction, though the overall contribution of HIV versus HAART remains debated.

Conclusions:

• Endothelial dysfunction and platelet alterations are key features of cardiovascular risk in chronic HIV infection.
• Both HIV infection itself and the long-term use of HAART may contribute to cardiovascular complications.
• Further research into pathophysiologic mechanisms and targeted therapies is warranted to mitigate cardiovascular risk in HIV patients.